Tools & Techniques

Getting higher-quality hits out of DNA-encoded libraries

DNA-encoded libraries are quickly surpassing traditional high throughput screens as industry’s first stop for hit generation. Now, developers are taking the technology up a notch to get more tractable hits in the output. DNA-encoded library...

Enzymes aim to beat chemistry by creating longer, speedier, cleaner DNA strands

The first new chemistry for DNA writing in 30 years is gathering steam, with enzymatic synthesis startups developing platforms to generate longer, purer DNA strands in record time. While the new players aim to outperform...

Lasker honors creators of Herceptin

This year’s suite of Lasker Foundation awards includes recognition of the scientists that created anti-HER2 mAb Herceptin trastuzumab, one of the first transformative therapies to come out of biotech, and one that remains standard of...

Gene editing companies say human germline editing ‘currently inappropriate’

Thirteen gene editing companies asserted that human germline gene editing is “currently inappropriate” in a statement released by the Alliance for Regenerative Medicine on Tuesday. The companies cite unresolved “important safety, ethical, legal, and societal...

Digital makes its mark on cognition

Digital biomarkers of cognitive decline could be the antidote to the slop in the subjective tests on which clinical neurology programs often hinge. With proof of concept established in small clinical trials and bigger readouts...

The next frontier for single-cell analysis

With an explosion in scalability, single-cell analysis has begun to invade every aspect of drug development, with early benefits showing themselves in precision targeting. The field’s next challenge is to integrate a wider array of...

Checkpoint inhibitors are bringing oncolytic viruses back into the spotlight

Early clinical readouts for next-generation oncolytic viruses are hinting at high efficacy when combined with checkpoint inhibitors, and pharmas are off to the races to find the best pairings. After more than two decades of...

New CRISPR case to finally settle the score

The latest CRISPR patent case aims to do what the first didn’t: determine who gets rights to the gene editing technology in eukaryotic cells, a category that covers almost all the cell types that matter...

Latest CRISPR patent pool stops short at research applications

The announcement that the Broad Institute and MilliporeSigma will offer combined licenses to CRISPR IP is the latest step toward simplifying the CRISPR IP landscape, but the licenses will be limited to research applications. Given...

A mark up for RNA epigenetics

As a field, RNA epigenetics is still in its infancy, though picking up pace as researchers translate lab findings to drug development. Two papers straddling academia and industry provide a new quantitative method that can...

Broadening role for external control arms in clinical trials

External control arms are moving from theory to practice as drug developers begin to use them to make internal go/no-go decisions for clinical programs and to support regulatory applications. The field is largely split between...

A new flavor of allosteric modulators: synthetic proteins

Relay co-founder and Brandeis Professor Dorothee Kern is turning to synthetic proteins rather than small molecules to drug targets at allosteric sites, a strategy she thinks will shorten the discovery process and provide added selectivity....

A human CRISPR-like system adds a new approach to regulating translation

A new system modeled on CRISPR and made entirely of human proteins is the latest strategy to intervene in gene control at the RNA translation level. The technology could bring higher levels of precision and...

GSK teams up with Doudna, Weissman labs to create CRISPR genomics center

GlaxoSmithKline’s latest move to reinvigorate R&D is a collaboration with two of the biggest names in CRISPR research to develop new gene editing technologies and use them to identify drug targets. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)...

FNIH consortium launches NIMBLE to validate non-invasive NASH biomarkers

The Foundation for the National Institutes of Health Biomarkers Consortium launched the five-year NIMBLE program on Tuesday to assess, standardize and validate non-invasive imaging and blood-based biomarkers for non-alcoholic steatohepatitis that could eventually replace liver...